EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Obio Technology (Group) EBITDA Margin % Related Terms
Shanghai Obio Technology (Group) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688238 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shanghai Obio Technology (Group)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Obio Technology (Group) EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Obio Technology (Group)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Obio Technology (Group)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Obio Technology (Group) (SHSE:688238) has a EBITDA Margin % of -100.09% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Obio Technology (Group) and its competitors. According to the industry distribution chart, Shanghai Obio Technology (Group) ranks #483 out of 942 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Shanghai Obio Technology (Group)'s EBITDA Margin % too high?
Shanghai Obio Technology (Group)'s current EBITDA Margin % is -100.09%. Based on the distribution chart, Shanghai Obio Technology (Group) ranks #483 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Obio Technology (Group) has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Obio Technology (Group)'s EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Obio Technology (Group) ranks #483 out of 942 companies for EBITDA Margin %. This places Shanghai Obio Technology (Group) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Obio Technology (Group) and its competitors. Shanghai Obio Technology (Group)'s current EBITDA Margin % is -100.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Obio Technology (Group) stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) (SHSE:688238) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.77, compared to a current price of ¥5.48 — trading 29.5% below its estimated fair value. The current EBITDA Margin % is -100.09%. Shanghai Obio Technology (Group)'s overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Obio Technology (Group) (SHSE:688238), the current EBITDA Margin % is -100.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Obio Technology (Group) (SHSE:688238) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) stock appears to be undervalued.
The current stock price of ¥5.48 is trading 29.5% below its estimated GF Value™ of ¥7.77.
GuruFocus considers Shanghai Obio Technology (Group) to be Modestly Undervalued.
Key valuation signals for SHSE:688238:
EBITDA Margin %: -100.09%
GF Value™: ¥7.77 vs. price of ¥5.48 (29.5% below fair value)
No single metric tells the full story. See the SHSE:688238 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Obio Technology (Group) Business Description
Shanghai Obio Technology (Group) Corp Ltd provides contract research organization (CRO) services, including gene therapy vector development and gene function research for basic research, as well as contract development and manufacturing organization (CDMO) services, including IND-enabling CMC research and GMP production of clinical samples for gene therapy drug development.
63GF Score
Get the complete analysis for SHSE:688238
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688238 has been successfully added to your 
